#BEGIN_DRUGCARD DB00518

# AHFS_Codes:
Not Available

# ATC_Codes:
P02CA03

# Absorption:
Poorly absorbed from the gastrointestinal tract due to its low aqueous solubility. Oral bioavailability appears to be enhanced when coadministered with a fatty meal (estimated fat content 40 g)

# Biotransformation:
Hepatic. Rapidly converted in the liver to the primary metabolite, albendazole sulfoxide, which is further metabolized to albendazole sulfone and other primary oxidative metabolites that have been identified in human urine.

# Brand_Mixtures:
Not Available

# Brand_Names:
Albenza
Eskazole
Valbazen
Zentel

# CAS_Registry_Number:
54965-21-8

# ChEBI_ID:
16664

# Chemical_Formula:
C12H15N3O2S

# Chemical_IUPAC_Name:
methyl N-[6-(propylsulfanyl)-1H-1,3-benzodiazol-2-yl]carbamate

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
1904779

# Description:
A benzimidazole broad-spectrum anthelmintic structurally related to mebendazole that is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38)

# Dosage_Forms:
Tablet, film coated	Oral

# Drug_Category:
Anthelmintics
Anticestodal Agents
Antiprotozoal Agents
Tubulin Modulators

# Drug_Interactions:
Not Available

# Drug_Reference:
11110097	Oxberry ME, Reynoldson JA, Thompson RC: The binding and distribution of albendazole and its principal metabolites in Giardia duodenalis. J Vet Pharmacol Ther. 2000 Jun;23(3):113-20.
11343808	Ramirez T, Benitez-Bribiesca L, Ostrosky-Wegman P, Herrera LA: In vitro effects of albendazole and its metabolites on the cell proliferation kinetics and micronuclei frequency of stimulated human lymphocytes. Arch Med Res. 2001 Mar-Apr;32(2):119-22.
17350811	Molina AJ, Merino G, Prieto JG, Real R, Mendoza G, Alvarez AI: Absorption and metabolism of albendazole after intestinal ischemia/reperfusion. Eur J Pharm Sci. 2007 May;31(1):16-24. Epub 2007 Feb 6.
8228321	Haque A, Hollister WS, Willcox A, Canning EU: The antimicrosporidial activity of albendazole. J Invertebr Pathol. 1993 Sep;62(2):171-7.

# Drug_Type:
Approved
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
2.7

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Practically insoluble

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Albendazole

# HET_ID:
ALW

# Half_Life:
Terminal elimination half-life ranges from 8 to 12 hours (single dose, 400mg).

# InChI_Identifier:
InChI=1S/C12H15N3O2S/c1-3-6-18-8-4-5-9-10(7-8)14-11(13-9)15-12(16)17-2/h4-5,7H,3,6H2,1-2H3,(H2,13,14,15,16)

# InChI_Key:
InChIKey=HXHWSAZORRCQMX-UHFFFAOYSA-N

# Indication:
For the treatment of parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm, <i>Taenia solium</i> and for the treatment of cystic hydatid disease of the liver, lung, and peritoneum, caused by the larval form of the dog tapeworm, <i>Echinococcus granulosus</i>.

# KEGG_Compound_ID:
C01779

# KEGG_Drug_ID:
D00134

# LIMS_Drug_ID:
518

# Mechanism_Of_Action:
Albendazole causes degenerative alterations in the tegument and intestinal cells of the worm by binding to the colchicine-sensitive site of tubulin, thus inhibiting its polymerization or assembly into microtubules. The loss of the cytoplasmic microtubules leads to impaired uptake of glucose by the larval and adult stages of the susceptible parasites, and depletes their glycogen stores. Degenerative changes in the endoplasmic reticulum, the mitochondria of the germinal layer, and the subsequent release of lysosomes result in decreased production of adenosine triphosphate (ATP), which is the energy required for the survival of the helminth. Due to diminished energy production, the parasite is immobilized and eventually dies.

# Melting_Point:
209 Â°C

# Molecular_Weight_Avg:
265.331

# Molecular_Weight_Mono:
265.088497429

# Organisms_Affected:
Helminthic Microorganisms

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
PA164746058

# Pharmacology:
Albendazole is a broad-spectrum anthelmintic. The principal mode of action for albendazole is by its inhibitory effect on tubulin polymerization which results in the loss of cytoplasmic microtubules.

# Predicted_LogP_Hydrophobicity:
3.22

# Predicted_LogS:
-4.1

# Predicted_Water_Solubility:
2.28e-02 g/l

# Primary_Accession_No:
DB00518

# Protein_Binding:
70% bound to plasma protein

# PubChem_Compound_ID:
2082

# PubChem_Substance_ID:
46506472

# RxList_Link:
http://www.rxlist.com/cgi/generic/albendazole.htm

# Salts:
Not Available

# Secondary_Accession_No:
APRD00782

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Symptoms of overdose include elevated liver enzymes, headaches, hair loss, low levels of white blood cells (neutropenia), fever, and itching.

# Update_Date:
2013-02-08 16:19:24 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Albendazole

# pKa_Isoelectric_Point:
Not Available

# Phase_1_Metabolizing_Enzyme_1_Gene_Name:
CYP1A2

# Phase_1_Metabolizing_Enzyme_1_ID:
4200

# Phase_1_Metabolizing_Enzyme_1_Name:
Cytochrome P450 1A2

# Phase_1_Metabolizing_Enzyme_1_Protein_Sequence:
>Cytochrome P450 1A2
MALSQSVPFSATELLLASAIFCLVFWVLKGLRPRVPKGLKSPPEPWGWPLLGHVLTLGKN
PHLALSRMSQRYGDVLQIRIGSTPVLVLSRLDTIRQALVRQGDDFKGRPDLYTSTLITDG
QSLTFSTDSGPVWAARRRLAQNALNTFSIASDPASSSSCYLEEHVSKEAKALISRLQELM
AGPGHFDPYNQVVVSVANVIGAMCFGQHFPESSDEMLSLVKNTHEFVETASSGNPLDFFP
ILRYLPNPALQRFKAFNQRFLWFLQKTVQEHYQDFDKNSVRDITGALFKHSKKGPRASGN
LIPQEKIVNLVNDIFGAGFDTVTTAISWSLMYLVTKPEIQRKIQKELDTVIGRERRPRLS
DRPQLPYLEAFILETFRHSSFLPFTIPHSTTRDTTLNGFYIPKKCCVFVNQWQVNHDPEL
WEDPSEFRPERFLTADGTAINKPLSEKMMLFGMGKRRCIGEVLAKWEIFLFLAILLQQLE
FSVPPGVKVDLTPIYGLTMKHARCEHVQARRFSIN

# Phase_1_Metabolizing_Enzyme_1_SwissProt_ID:
P05177

# Phase_1_Metabolizing_Enzyme_2_Gene_Name:
CYP3A4

# Phase_1_Metabolizing_Enzyme_2_ID:
4512

# Phase_1_Metabolizing_Enzyme_2_Name:
Cytochrome P450 3A4

# Phase_1_Metabolizing_Enzyme_2_Protein_Sequence:
>Cytochrome P450 3A4
MALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNILSYHKGFCMF
DMECHKKYGKVWGFYDGQQPVLAITDPDMIKTVLVKECYSVFTNRRPFGPVGFMKSAISI
AEDEEWKRLRSLLSPTFTSGKLKEMVPIIAQYGDVLVRNLRREAETGKPVTLKDVFGAYS
MDVITSTSFGVNIDSLNNPQDPFVENTKKLLRFDFLDPFFLSITVFPFLIPILEVLNICV
FPREVTNFLRKSVKRMKESRLEDTQKHRVDFLQLMIDSQNSKETESHKALSDLELVAQSI
IFIFAGYETTSSVLSFIMYELATHPDVQQKLQEEIDAVLPNKAPPTYDTVLQMEYLDMVV
NETLRLFPIAMRLERVCKKDVEINGMFIPKGVVVMIPSYALHRDPKYWTEPEKFLPERFS
KKNKDNIDPYIYTPFGSGPRNCIGMRFALMNMKLALIRVLQNFSFKPCKETQIPLKLSLG
GLLQPEKPVVLKVESRDGTVSGA

# Phase_1_Metabolizing_Enzyme_2_SwissProt_ID:
P08684

# Phase_1_Metabolizing_Enzyme_3_Gene_Name:
CYP1A1

# Phase_1_Metabolizing_Enzyme_3_ID:
6024

# Phase_1_Metabolizing_Enzyme_3_Name:
Cytochrome P450 1A1

# Phase_1_Metabolizing_Enzyme_3_Protein_Sequence:
>Cytochrome P450 1A1
MLFPISMSATEFLLASVIFCLVFWVIRASRPQVPKGLKNPPGPWGWPLIGHMLTLGKNPH
LALSRMSQQYGDVLQIRIGSTPVVVLSGLDTIRQALVRQGDDFKGRPDLYTFTLISNGQS
MSFSPDSGPVWAARRRLAQNGLKSFSIASDPASSTSCYLEEHVSKEAEVLISTLQELMAG
PGHFNPYRYVVVSVTNVICAICFGRRYDHNHQELLSLVNLNNNFGEVVGSGNPADFIPIL
RYLPNPSLNAFKDLNEKFYSFMQKMVKEHYKTFEKGHIRDITDSLIEHCQEKQLDENANV
QLSDEKIINIVLDLFGAGFDTVTTAISWSLMYLVMNPRVQRKIQEELDTVIGRSRRPRLS
DRSHLPYMEAFILETFRHSSFVPFTIPHSTTRDTSLKGFYIPKGRCVFVNQWQINHDQKL
WVNPSEFLPERFLTPDGAIDKVLSEKVIIFGMGKRKCIGETIARWEVFLFLAILLQRVEF
SVPLGVKVDMTPIYGLTMKHACCEHFQMQLRS

# Phase_1_Metabolizing_Enzyme_3_SwissProt_ID:
P04798

# Drug_Target_1_Cellular_Location:
Cytoplasmic

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
11343808	Ramirez T, Benitez-Bribiesca L, Ostrosky-Wegman P, Herrera LA: In vitro effects of albendazole and its metabolites on the cell proliferation kinetics and micronuclei frequency of stimulated human lymphocytes. Arch Med Res. 2001 Mar-Apr;32(2):119-22.
19846910	Chu SW, Badar S, Morris DL, Pourgholami MH: Potent inhibition of tubulin polymerisation and proliferation of paclitaxel-resistant 1A9PTX22 human ovarian cancer cells by albendazole. Anticancer Res. 2009 Oct;29(10):3791-6.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
TUBA1A

# Drug_Target_1_GenBank_ID_Gene:
X01703

# Drug_Target_1_GenBank_ID_Protein:
37492

# Drug_Target_1_GeneCard_ID:
TUBA1A

# Drug_Target_1_Gene_Name:
TUBA1A

# Drug_Target_1_Gene_Sequence:
>1356 bp
ATGCGTGAGTGCATCTCCATCCACGTTGGCCAGGCTGGTGTCCAGATTGGCAATGCCTGC
TGGGAGCTCTACTGCCTGGAACACGGCATCCAGCCCGATGGCCAGATGCCAAGTGACAAG
ACCATTGGGGGAGGAGATGATTCCTTCAACACCTTCTTCAGTGAGACGGGGGCTGGCAAG
CATGTGCCCCGGGCAGTGTTTGTAGACTTGGAACCCACAGTCATTGATGAAGTTCGCACT
GGCACCTACCGCCAGCTCTTCCACCCTGAGCAACTCATCACAGGCAAAGAAGATGCTGCC
AATAACTATGCCCGAGGGCACTACACCATTGGCAAGGAGATCATTGACCTCGTGTTGGAC
CGAATTCGCAAGCTGGCCGACCAGTGCACGCGTCTCCAGGGCTTCTTGGTTTTCCACAGC
TTTGGTGGGGGAACTGGTTCTGGGTTCACCTCGCTGCTCATGGAACGTCTCTCAGTTGAT
TATGGCAAGAAGTCCAAGCTGGAGTTCTCTATTTACCCGGCGCCCCAGGTTTCCACAGCT
GTAGTTGAGCCCTACAACTCCATCCTCACCACCCACACCACCCTGGAGCACTCTGATTGT
GCCTTCATGGTAGACAATGAGGCCATCTATGACATCTGTCGTAGAAACCTCGATATTGAG
CGTCCAACCTATACTAACCTGAATAGGTTAATAGGTCAAATTGTGTCCTCCATCACTGCT
TCCCTGAGATTTGATGGAGCCCTGAATGTTGACCTGACAGAATTCCAGACCAACCTGGTG
CCCTATCCCCGCATCCACTTCCCTCTGGCCACATATGCCCCTGTCATCTCTGCTGAGAAA
GCCTACCATGAACAGCTTTCTGTAGCAGAGATCACCAATGCTTGCTTTGAGCCAGCCAAC
CAGATGGTGAAATGTGACCCTGGCCATGGTAAATACATGGCTTGCTGCCTGTTGTACCGT
GGTGACGTGGTTCCCAAAGATGTCAATGCTGCCATTGCCACCATCAAGACCAAGCGTACC
ATCCAGTTTGTGGATTGGTGCCCCACTGGCTTCAAGGTTGGCATCAACTACCAGCCTCCC
ACTGTGGTGCCTGGTGGAGACCTGGCCAAGGTACAGAGAGCTGTGTGCATGCTGAGCAAC
ACCACAGCCATTGCTGAGGCCTGGGCTCGCCTGGACCACAAGTTTGACCTGATGTATGCC
AAACGTGCCTTTGTTCACTGGTACGTTGGGGAGGGGATGGAGGAAGGTGAGTTTTCAGAG
GCCCGTGAGGACATGGCTGCCCTTGAGAAGGATTATGAGGAGGTTGGTGTGCATTCTGTT
GAAGGAGAGGGTGAGGAAGAAGGAGAGGAATACTAA

# Drug_Target_1_General_Function:
Involved in structural molecule activity

# Drug_Target_1_General_References:
11504633	Crabtree DV, Ojima I, Geng X, Adler AJ: Tubulins in the primate retina: evidence that xanthophylls may be endogenous ligands for the paclitaxel-binding site. Bioorg Med Chem. 2001 Aug;9(8):1967-76.
3839072	Hall JL, Cowan NJ: Structural features and restricted expression of a human alpha-tubulin gene. Nucleic Acids Res. 1985 Jan 11;13(1):207-23.
6646120	Cowan NJ, Dobner PR, Fuchs EV, Cleveland DW: Expression of human alpha-tubulin genes: interspecies conservation of 3' untranslated regions. Mol Cell Biol. 1983 Oct;3(10):1738-45.

# Drug_Target_1_HGNC_ID:
HGNC:20766

# Drug_Target_1_HPRD_ID:
03959

# Drug_Target_1_ID:
2449

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
50136

# Drug_Target_1_Name:
Tubulin alpha-3 chain

# Drug_Target_1_Number_of_Residues:
451

# Drug_Target_1_PDB_ID:
1SA1

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00091	Tubulin
PF03953	Tubulin_C

# Drug_Target_1_Protein_Sequence:
>Tubulin alpha-3 chain
MRECISIHVGQAGVQIGNACWELYCLEHGIQPDGQMPSDKTIGGGDDSFNTFFSETGAGK
HVPRAVFVDLEPTVIDEVRTGTYRQLFHPEQLITGKEDAANNYARGHYTIGKEIIDLVLD
RIRKLADQCTGLQGFLVFHSFGGGTGSGFTSLLMERLSVDYGKKSKLEFSIYPAPQVSTA
VVEPYNSILTTHTTLEHSDCAFMVDNEAIYDICRRNLDIERPTYTNLNRLIGQIVSSITA
SLRFDGALNVDLTEFQTNLVPYPRIHFPLATYAPVISAEKAYHEQLSVAEITNACFEPAN
QMVKCDPRHGKYMACCLLYRGDVVPKDVNAAIATIKTKRTIQFVDWCPTGFKVGINYQPP
TVVPGGDLAKVQRAVCMLSNTTAIAEAWARLDHKFDLMYAKRAFVHWYVGEGMEEGEFSE
AREDMAALEKDYEEVGVDSVEGEGEEEGEEY

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Tubulin is the major constituent of microtubules. It binds two moles of GTP, one at an exchangeable site on the beta chain and one at a non-exchangeable site on the alpha-chain

# Drug_Target_1_SwissProt_ID:
Q71U36

# Drug_Target_1_SwissProt_Name:
TBA1A_HUMAN

# Drug_Target_1_Synonyms:
Alpha-tubulin 3
Tubulin B-alpha-1

# Drug_Target_1_Theoretical_pI:
4.70

# Drug_Target_1_Transmembrane_Regions:
None

# Drug_Target_2_Cellular_Location:
Cytoplasmic

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
11980387	Solana HD, Sallovitz JM, Lanusse CE, Rodriguez JA: Enantioselective binding of albendazole sulphoxide to cytosolic proteins from helminth parasites. Methods Find Exp Clin Pharmacol. 2002 Jan-Feb;24(1):7-13.
19846910	Chu SW, Badar S, Morris DL, Pourgholami MH: Potent inhibition of tubulin polymerisation and proliferation of paclitaxel-resistant 1A9PTX22 human ovarian cancer cells by albendazole. Anticancer Res. 2009 Oct;29(10):3791-6.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
TUBB2C

# Drug_Target_2_GenBank_ID_Gene:
X02344

# Drug_Target_2_GenBank_ID_Protein:
37494

# Drug_Target_2_GeneCard_ID:
TUBB2C

# Drug_Target_2_Gene_Name:
TUBB2C

# Drug_Target_2_Gene_Sequence:
>1338 bp
ATGAGGGAAATCGTGCACTTGCAGGCCGGGCAGTGCGGCAACCAAATCGGCGCCAAGTTT
TGGGAGGTGATCAGCGATGAGCACGGCATCGACCCCACGGGCACCTACCACGGGGACAGC
GACCTGCAGCTGGAACGCATCAACGTGTACTACAATGAGGCCACCGGCGGCAAGTACGTG
CCCCGCGCCGTGCTCGTGGATCTGGAGCCCGGCACCATGGACTCCGTGCGGTCGGGGCCC
TTCGGGCAGATCTTCCGGCCGGACAACTTCGTTTTCGGTCAGAGTGGTGCTGGGAACAAC
TGGGCCAAGGGGCACTACACAGAAGGCGCGGAGCTGGTGGACTCGGTGCTGGATGTTGTG
AGAAAGGAGGCTGAGAGCTGTGACTGCCTGCAGGGTTTCCAGCTGACCCACTCCCTGGGT
GGGGGGACTGGGTCTGGGATGGGTACCCTCCTCATCAGCAAGATCCGGGAGGAGTACCCA
GACAGGATCATGAACACGTTTAGTGTGGTGCCTTCGCCCAAAGTGTCAGACACAGTGGTG
GAGCCCTACAACGCCACCCTCTCAGTCCACCAGCTCGTAGAAAACACAGACGAGACCTAC
TGCATTGATAACGAAGCTCTCTACGACATTTGCTTCAGAACCCTAAAGCTGACCACGCCC
ACCTATGGTGACCTGAACCACCTGGTGTCTGCTACCATGAGTGGGGTCACCACCTGCCTG
CGCTTCCCAGGCCAGCTCAATGCTGACCTGCGGAAGCTGGCTGTGAACATGGTCCCGTTT
CCCCGGCTGCACTTCTTCATGCCCGGCTTTGCCCCACTGACCAGCCGGGGCAGCCAGCAG
TACCGGGCGCTGACCGTGCCCGAGCTCACCCAGCAGATGTTTGATGCCAAGAACATGATG
GCTGCCTGCGACCCCCGCCATGGCCGCTACCTGACGGTTGCCGCCGTGTTCAGGGGCCGG
ATGTCCATGAAGGAGGTGGATGAGCAAATGCTTAATGTCCAAAACAAAAACAGCAGCTAT
TTTGTTGAGTGGATCCCCAACAATGTGAAAACGGCTGTCTGTGACATCCCACCTCGGGGG
CTAAAAATGTCCGCCACCTTCATTGGCAACAGCACGGCCATCCAGGAGCTGTTCAAGCGC
ATCTCCGAGCAGTTCACGGCCATGTTCCGGCGCAAGGCCTTCCTGCACTGGTACACGGGC
GAGGGCATGGACGAGATGGAGTTCACCGAGGCCGAGAGCAACATGAATGACCTGGTGTCC
GAGTACCAGCAGTACCAGGATGCCACAGCCGAGGAGGAGGGCGAGTTCGAGGAGGAGGCT
GAGGAGGAGGTGGCCTAG

# Drug_Target_2_General_Function:
Cell cycle control, cell division, chromosome partitioning

# Drug_Target_2_General_References:
3999141	Lewis SA, Gilmartin ME, Hall JL, Cowan NJ: Three expressed sequences within the human beta-tubulin multigene family each define a distinct isotype. J Mol Biol. 1985 Mar 5;182(1):11-20.

# Drug_Target_2_HGNC_ID:
HGNC:20771

# Drug_Target_2_HPRD_ID:
04043

# Drug_Target_2_ID:
2499

# Drug_Target_2_Locus:
9q34

# Drug_Target_2_Molecular_Weight:
49832

# Drug_Target_2_Name:
Tubulin beta-2C chain

# Drug_Target_2_Number_of_Residues:
445

# Drug_Target_2_PDB_ID:
1SA1

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF00091	Tubulin
PF03953	Tubulin_C

# Drug_Target_2_Protein_Sequence:
>Tubulin beta-2C chain
MREIVHLQAGQCGNQIGAKFWEVISDEHGIDPTGTYHGDSDLQLERINVYYNEATGGKYV
PRAVLVDLEPGTMDSVRSGPFGQIFRPDNFVFGQSGAGNNWAKGHYTEGAELVDSVLDVV
RKEAESCDCLQGFQLTHSLGGGTGSGMGTLLISKIREEYPDRIMNTFSVVPSPKVSDTVV
EPYNATLSVHQLVENTDETYCIDNEALYDICFRTLKLTTPTYGDLNHLVSATMSGVTTCL
RFPGQLNADLRKLAVNMVPFPRLHFFMPGFAPLTSRGSQQYRALTVPELTQQMFDAKNMM
AACDPRHGRYLTVAAVFRGRMSMKEVDEQMLNVQNKNSSYFVEWIPNNVKTAVCDIPPRG
LKMSATFIGNSTAIQELFKRISEQFTAMFRRKAFLHWYTGEGMDEMEFTEAESNMNDLVS
EYQQYQDATAEEEGEFEEEAEEEVA

# Drug_Target_2_Reaction:
Not Available

# Drug_Target_2_Signals:
None

# Drug_Target_2_Specific_Function:
Tubulin is the major constituent of microtubules. It binds two moles of GTP, one at an exchangeable site on the beta chain and one at a non-exchangeable site on the alpha-chain

# Drug_Target_2_SwissProt_ID:
P68371

# Drug_Target_2_SwissProt_Name:
TBB2C_HUMAN

# Drug_Target_2_Synonyms:
Tubulin beta-2 chain

# Drug_Target_2_Theoretical_pI:
4.52

# Drug_Target_2_Transmembrane_Regions:
None

# Drug_Target_3_Cellular_Location:
Periplasm

# Drug_Target_3_Chromosome_Location:
Not Available

# Drug_Target_3_Drug_References:
6518278	Barrowman MM, Marriner SE, Bogan JA: The fumarate reductase system as a site of anthelmintic attack in Ascaris suum. Biosci Rep. 1984 Oct;4(10):879-83.

# Drug_Target_3_Essentiality:
Non-Essential

# Drug_Target_3_GenAtlas_ID:
Not Available

# Drug_Target_3_GenBank_ID_Gene:
AE014299

# Drug_Target_3_GenBank_ID_Protein:
24346572

# Drug_Target_3_GeneCard_ID:
Not Available

# Drug_Target_3_Gene_Name:
SO_0970

# Drug_Target_3_Gene_Sequence:
>1791 bp
TTAATTATCTTTAGCGAATTTAGCGGCAGATGCACCCGCGATACGGCCGTAGGTGACGAT
ATCAGAGATAGCGTTACCACCTAAACGGTTAGCACCGTGAACACCACCAGTCACTTCGCC
TGCAGCGTATAAACCAGTGATAGGTTTACCGGTTTTCTCACTCTTCACTTCGGCTTTAGT
ATCAATCACCAGACCACCCATAGTGTGGTGAACCGCTGGTGCAATTTCTAAGGCGTAGAA
AGGAGCTACCACTAATTCACGTGGTAAATCAGGACGTTCAAATTGAGCATCTTTACCTGA
TTTAACGAAACCGTTGTAGGCTGTTACTGTTTTTGCCAATTCAGCTGCAGGTACATCGAT
TTGTTTCGCTAACTCTTCGATGGTTTTACCTTCTTTTACAATGTTCAGGTGAACATAACC
TTCGATGGCCTTCAAGCTCTTACGGATAGAGTCATCGAATACTAGGTAAGCGCTTTCACC
TTTTTGTTGCAGAATCGCCGCAGACGCTTTATCACGGGTGGTGATTTCGTTCATAAAACG
ATTACCTTCACGGTTCACCACGATTGCACCGTTACCACGTACTGCCTCGGTGATCATCAC
GCCACCCGCTGGAGAGTAAGTTGGGTGAGCTTGGATGTATTCTAAGTCACGTGTTGCTGC
GCCCGCTTGTAGAGCTACGTCTAAGCCGTCACCCGTCGCACCTGGGTGGTTGGTCGCTTT
AAAGCCTTTTAACTTAGGATCGTATTTAGAAACACGTTCGTTGTTTTTCGCAAAACCACC
TGCTGCAATGACTACTGCATCGGCTTTGATCACATAGTAACCTGTGTATTCACCTTTCAC
TAAAACGCCGGTCACTTTACCGCTTGCATCTTCAAGGATGCGCACAACGCGGCTGTTTAA
GCGAATATCAGTACCACGCTTAACGGCGTTGTCCCACAGCACTTGTGCTACGTGAGCACC
AACACCTGCACCACCGGTTGGACGGTGACTACGGTTAACGCTCGCGCCACCCATACGACC
CACGTCAGTCATGTCGGCACCCATAGAGGTTAACCAATCGATTGAGTCTGAAGAGTTGTT
AGCCAGTACTTTAACTAATTCAGGATCGTTGATGTTGCGGCCACCTTTCATAGTGTCGTC
GATCATGATTTGTTTCTTATCTTCGATACCTAACTTAGCCTGTGGCTTAGTTTCTGCGGC
GTTCATACCACCGGCAGCCAGTTTAGTGTTACCACCTGGGATAGGTTCTTTTTCTAACAG
AATCACTTTCGCGCCAGCATCACGGGCAGATACGGCAGCGGCAAGACCAGCACCACCAGA
GCCGATAATTACAACGTCTGTGGTTTCTTTCACACCAGCAGCAATGGCTTTATCTTGTGC
TGCTTTGTCTGCATCAACAGGTACAAACTTACGTTCCCACTTGCCACCAAATGGCATATC
GAAGCCGAAGCTATGGCAAGCATCACAATAAGCTACTGATTTTTCGTGGCCTTTGTGGCA
GCTCGTACAAGCGATTTCACCAATTAAGTGAGATTTGTGCGGAGAAACTTTATCTTTAGG
CGCTGCTGCAGCCAGTTCTTTTAAGTCACCGTGGCAGCTAACACATTGGCCATTCTCATG
GGTCAGGTTGTCGTTAGTCACGCCACCTTTGTCTGATACGTGGCAGCTATCGCAGCCACC
CATTTCACCGTGAAAATCGGCTAGTACTTCTGGAGCGGCATAGGCTGTGCCTGCCATTGC
GCCAGAGATCAGCATGGCTAGTGCTGTTTTTTGAATCTTTCTTGTGAACAT

# Drug_Target_3_General_Function:
Energy production and conversion

# Drug_Target_3_General_References:
10581551	Leys D, Tsapin AS, Nealson KH, Meyer TE, Cusanovich MA, Van Beeumen JJ: Structure and mechanism of the flavocytochrome c fumarate reductase of Shewanella putrefaciens MR-1. Nat Struct Biol. 1999 Dec;6(12):1113-7.
11425747	Tsapin AI, Vandenberghe I, Nealson KH, Scott JH, Meyer TE, Cusanovich MA, Harada E, Kaizu T, Akutsu H, Leys D, Van Beeumen JJ: Identification of a small tetraheme cytochrome c and a flavocytochrome c as two of the principal soluble cytochromes c in Shewanella oneidensis strain MR1. Appl Environ Microbiol. 2001 Jul;67(7):3236-44.
12368813	Heidelberg JF, Paulsen IT, Nelson KE, Gaidos EJ, Nelson WC, Read TD, Eisen JA, Seshadri R, Ward N, Methe B, Clayton RA, Meyer T, Tsapin A, Scott J, Beanan M, Brinkac L, Daugherty S, DeBoy RT, Dodson RJ, Durkin AS, Haft DH, Kolonay JF, Madupu R, Peterson JD, Umayam LA, White O, Wolf AM, Vamathevan J, Weidman J, Impraim M, Lee K, Berry K, Lee C, Mueller J, Khouri H, Gill J, Utterback TR, McDonald LA, Feldblyum TV, Smith HO, Venter JC, Nealson KH, Fraser CM: Genome sequence of the dissimilatory metal ion-reducing bacterium Shewanella oneidensis. Nat Biotechnol. 2002 Nov;20(11):1118-23. Epub 2002 Oct 7.

# Drug_Target_3_HGNC_ID:
Not Available

# Drug_Target_3_HPRD_ID:
Not Available

# Drug_Target_3_ID:
2709

# Drug_Target_3_Locus:
Not Available

# Drug_Target_3_Molecular_Weight:
62448

# Drug_Target_3_Name:
Fumarate reductase flavoprotein subunit

# Drug_Target_3_Number_of_Residues:
596

# Drug_Target_3_PDB_ID:
1D4C

# Drug_Target_3_Pathway:
Not Available

# Drug_Target_3_Pfam_Domain_Function:
PF00890	FAD_binding_2

# Drug_Target_3_Protein_Sequence:
>Fumarate reductase flavoprotein subunit precursor
MFTRKIQKTALAMLISGAMAGTAYAAPEVLADFHGEMGGCDSCHVSDKGGVTNDNLTHEN
GQCVSCHGDLKELAAAAPKDKVSPHKSHLIGEIACTSCHKGHEKSVAYCDACHSFGFDMP
FGGKWERKFVPVDADKAAQDKAIAAGVKETTDVVIIGSGGAGLAAAVSARDAGAKVILLE
KEPIPGGNTKLAAGGMNAAETKPQAKLGIEDKKQIMIDDTMKGGRNINDPELVKVLANNS
SDSIDWLTSMGADMTDVGRMGGASVNRSHRPTGGAGVGAHVAQVLWDNAVKRGTDIRLNS
RVVRILEDASGKVTGVLVKGEYTGYYVIKADAVVIAAGGFAKNNERVSKYDPKLKGFKAT
NHPGATGDGLDVALQAGAATRDLEYIQAHPTYSPAGGVMITEAVRGNGAIVVNREGNRFM
NEITTRDKASAAILQQKGESAYLVFDDSIRKSLKAIEGYVHLNIVKEGKTIEELAKQIDV
PAAELAKTVTAYNGFVKSGKDAQFERPDLPRELVVAPFYALEIAPAVHHTMGGLVIDTKA
EVKSEKTGKPITGLYAAGEVTGGVHGANRLGGNAISDIVTYGRIAGASAAKFAKDN

# Drug_Target_3_Reaction:
succinate + acceptor = fumarate + reduced acceptor

# Drug_Target_3_Signals:
1-25

# Drug_Target_3_Specific_Function:
Catalyzes fumarate reduction using artificial electron donors such as methyl viologen. The physiological reductant is unknown, but evidence indicates that flavocytochrome c participates in electron transfer from formate to fumarate and possibly also to trimethylamine oxide (TMAO). This enzyme is essentially unidirectional

# Drug_Target_3_SwissProt_ID:
P83223

# Drug_Target_3_SwissProt_Name:
FRDA_SHEON

# Drug_Target_3_Synonyms:
EC 1.3.99.1
FL cyt
Flavocytochrome c
Fumarate reductase flavoprotein subunit precursor

# Drug_Target_3_Theoretical_pI:
7.64

# Drug_Target_3_Transmembrane_Regions:
None

#END_DRUGCARD DB00518
